All In Biotech

Drug Trial Radar · NCT05886868

Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors

A Phase I, International, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of BL0020 as A Single Agent in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

66

Planned (sponsor's estimate)

Start

Oct 24, 2023

Primary completion

Jul 2024

Study completion Feb 2025

Sponsor

Sponsor type
Industry
First posted
Jun 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is the first in human study of BL0020, and the primary objective is to evaluate the safety and tolerability, and determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of BL0020 as a single agent in patients with advanced solid tumors. This study consists of two parts: Part A (dose escalation stage) and Part B (dose expansion stage). The study includes screening, treatment and follow-up periods. In part A, "3+ 3" will be used for dose escalation. In part B, the dose level and/or enrolled patient population for dose-expansion may be adjusted based on available data on the safety, PK and preliminary efficacy gained from the patients.

Conditions

  • Advanced Solid Tumor

Interventions

  • BL0020Drug

    Dose Escalation Stage: BL0020 will be administered via intravenous infusion on days 1 of a 21-days treatment cycle. Dose Expansion Stage: Maximum tolerated dose or the recommended Phase 2 dose (RP2D) from dose escalation Stage.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose(MTD)Time frame: Throughout the study for approximately 2 years
  2. Recommended Phase II Dose(RP2D)Time frame: Throughout the study for approximately 2 years

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Cancer Care Foundation Limited

    Sydney, New South Wales, Australia · Active not recruiting

  • Scientia Clinical Research

    Sydney, New South Wales, Australia · Recruiting

  • Sunshine Coast University Private Hospital

    Birtinya, Queensland, Australia · Active not recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.